T1	Parsing_Error 0 56	-Patients residing in the following clinical states wit!
T2	Parsing_Error 57 74	be considered: A.
T3	Measurement 82 85	PSA
T4	Value 75 81	Rising
R1	Has_value Arg1:T3 Arg2:T4	
T5	Observation 103 113	history of
T6	Condition 114 131	localized disease
T7	Procedure 162 171	radiation
T8	Procedure 175 182	surgery
*	OR T7 T8
T9	Qualifier 151 161	definitive
T10	Scope 162 182	radiation or surgery
R2	Has_qualifier Arg1:T10 Arg2:T9	
T11	Observation 216 238	progression of disease
T12	Qualifier 239 252	biochemically
R3	Has_qualifier Arg1:T11 Arg2:T12	
R4	Has_temporal Arg1:T6 Arg2:T5	
R5	Has_scope Arg1:T6 Arg2:T10	
T13	Qualifier 308 332	radiographically evident
T14	Condition 333 340	disease
R6	Has_qualifier Arg1:T14 Arg2:T13	
T15	Qualifier 346 358	Non-castrate
T16	Qualifier 359 369	metastatic
T17	Observation 398 419	radiographic evidence
T18	Procedure 398 410	radiographic
R7	Has_context Arg1:T18 Arg2:T17	
T19	Condition 423 441	metastatic disease
R8	AND Arg1:T18 Arg2:T19	
T20	Temporal 442 466	at the time of diagnosis
T21	Temporal 470 507	after treatment for localized disease
T22	Procedure 476 485	treatment
T23	Condition 490 507	localized disease
T24	Reference_point 476 507	treatment for localized disease
*	OR T20 T21
T25	Reference_point 445 466	the time of diagnosis
R9	Has_index Arg1:T20 Arg2:T25	
T26	Scope 442 507	at the time of diagnosis or after treatment for localized disease
R10	Has_scope Arg1:T19 Arg2:T26	
T27	Scope 346 369	Non-castrate metastatic
R11	Has_scope Arg1:T19 Arg2:T27	
T28	Temporal 534 548	newly detected
T29	Condition 549 556;580 587	disease in bone
T30	Condition 560 579;591 605	progressing disease in soft tissue
*	OR T29 T30 T31 T32
T31	Condition 549 556;591 605	disease in soft tissue
T32	Condition 560 587	progressing disease in bone
T33	Observation 607 630	Biochemical progression
T34	Measurement 736 773	Minimal % increase in range of values
T35	Value 775 778	50%
R12	Has_value Arg1:T34 Arg2:T35	
T36	Measurement 698 724	Minimal Baseline PSA value
T37	Value 725 735	(ng/ml): 2
R13	Has_value Arg1:T36 Arg2:T37	
T38	Measurement 646 675	minimum no. of determinations
T39	Value 677 678	3
R14	Has_value Arg1:T38 Arg2:T39	
T40	Measurement 679 687	Interval
T41	Value 689 697	>2 weeks
R15	Has_value Arg1:T40 Arg2:T41	
T42	Scope 646 778	minimum no. of determinations: 3 Interval: >2 weeks Minimal Baseline PSA value (ng/ml): 2 Minimal % increase in range of values: 50%
R16	Has_scope Arg1:T33 Arg2:T42	
T43	Scope 549 605	disease or progressing disease in bone or in soft tissue
R17	Has_temporal Arg1:T43 Arg2:T28	
R18	Has_context Arg1:T30 Arg2:T33	
R19	Has_context Arg1:T32 Arg2:T33	
T44	Condition 793 816	prostate adenocarcinoma
T45	Procedure 817 831	histologically
T46	Value 832 841	confirmed
T47	Qualifier 817 841	histologically confirmed
R20	Has_value Arg1:T45 Arg2:T46	
R21	multi Arg1:T47 Arg2:T45	
R22	Has_qualifier Arg1:T44 Arg2:T47	
T48	Measurement 871 898	level of serum testosterone
T49	Value 899 930	above the lower limit of normal
R23	Has_value Arg1:T48 Arg2:T49	
T50	Measurement 933 968	Karnofskcy performance status (KPS)
T51	Value 969 974	>_70%
R24	Has_value Arg1:T50 Arg2:T51	
T52	Value 996 1004	adequate
T53	Measurement 1005 1019	organ function
R25	Has_value Arg1:T53 Arg2:T52	
T54	Observation 996 1019	adequate organ function
R26	multi Arg1:T54 Arg2:T53	
T55	Measurement 1070 1073	WBC
T56	Value 1074 1084	>_3500/mm3
T57	Measurement 1086 1100	platelet count
T58	Value 1101 1114	>_100,000/mm3
R27	Has_value Arg1:T57 Arg2:T58	
R28	Has_value Arg1:T55 Arg2:T56	
T59	Measurement 1117 1126	Bilirubin
T60	Value 1127 1137	<2.0 mg/dl
T61	Measurement 1141 1145	SGOT
T62	Value 1146 1178	<3.0 X the upper limit of normal
R29	Has_value Arg1:T61 Arg2:T62	
R30	Has_value Arg1:T59 Arg2:T60	
*	OR T59 T61
T63	Measurement 1181 1191	Creatinine
T64	Value 1192 1203	<_1.6 mg/dl
T65	Measurement 1207 1227	creatinine clearance
T66	Value 1228 1239	>_60 cc/min
R31	Has_value Arg1:T65 Arg2:T66	
R32	Has_value Arg1:T63 Arg2:T64	
*	OR T63 T65
T67	Temporal 1242 1247	Prior
T68	Procedure 1248 1264	hormonal therapy
R33	Has_temporal Arg1:T68 Arg2:T67	
T69	Mood 1265 1275	is allowed
R34	Has_mood Arg1:T68 Arg2:T69	
T70	Procedure 1284 1305	Neoadjuvant treatment
T71	Temporal 1306 1357	prior to radiation therapy or radical prostatectomy
T72	Procedure 1315 1332	radiation therapy
T73	Procedure 1336 1357	radical prostatectomy
T74	Reference_point 1315 1357	radiation therapy or radical prostatectomy
*	OR T72 T73
R35	Has_index Arg1:T71 Arg2:T74	
R36	Has_temporal Arg1:T70 Arg2:T71	
T75	Measurement 1377 1403	total duration of exposure
T76	Value 1404 1429	does not exceed 10 months
R37	Has_value Arg1:T75 Arg2:T76	
R38	AND Arg1:T70 Arg2:T75	
T77	Multiplier 1435 1444	One cycle
T78	Procedure 1448 1468	intermittent therapy
R39	Has_multiplier Arg1:T78 Arg2:T77	
T79	Measurement 1477 1493	maximum exposure
T80	Value 1497 1506	10 months
R40	Has_value Arg1:T79 Arg2:T80	
R41	AND Arg1:T78 Arg2:T79	
T81	Value 1526 1543	at least 18 years
T82	Person 1547 1550	age
R42	Has_value Arg1:T82 Arg2:T81	
T83	Informed_consent 1572 1607	signed an informed consent document
